Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vidion system CE marked

This article was originally published in Clinica

Executive Summary

Fremont, California-based NeoVista has CE marked its Vidion wet age-related macular degeneration (AMD) therapy for sale in Europe. Vidion is an epimacular brachytherapy device which uses strontium 90 to target ionising beta radiation to choroidal neovascularisation – new blood vessels that have grown in connective tissue surrounding the eye. Blood leaking from this neovascularisation affects central vision, causing AMD.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel